Screener
CareDx CDNA Sales & Marketing
Sales & Marketing at other companies
Other financials
Where this comes from
Reported directly by CareDx in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: CareDx’s 10-Q, filed April 28, 2026.
- Filed
- Apr 28, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001217234-26-000033
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cost of product | 4,834 | 5,586 |
| Cost of patient and digital solutions | 11,698 | 7,716 |
| Research and development | 21,416 | 18,524 |
| Sales and marketing | 30,373 | 22,991 |
| General and administrative | 30,484 | 22,769 |
| Litigation settlement expense | 600 | 5,360 |
| Total operating expenses | 116,502 | 98,059 |
| Income (loss) from operations | 1,198 | (13,374) |
ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is CareDx's sales & marketing?
- CareDx (CDNA) reported sales & marketing of $30.37M in Q1 2026.
- How has CareDx's sales & marketing changed year-over-year?
- CareDx's sales & marketing increased by 32.1% year-over-year, from $22.99M to $30.37M.
- What is the long-term trend for CareDx's sales & marketing?
- Over 4 years (2021 to 2025), CareDx's sales & marketing has grown at a 7.4% compound annual growth rate (CAGR), from $77.25M to $102.64M.
- What does sales & marketing mean?
- Costs of selling products and services including sales force compensation, commissions, marketing campaigns, trade shows, and customer acquisition expenses.
Ask your AI about CareDx's sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude